2007
DOI: 10.1158/1078-0432.ccr-06-2701
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort.We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer. Experimental Design: Blood was collected from 63 patients with metastatic prostate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
216
0
1

Year Published

2009
2009
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 321 publications
(222 citation statements)
references
References 31 publications
5
216
0
1
Order By: Relevance
“…Assessment of CTC using CellSearch has been cleared by the Food and Drug Administration as a prognostic indicator, in conjunction with other clinical methods, for patients with metastatic breast, prostate, and colorectal cancers. Studies in metastatic breast, colorectal, and prostate cancer showed that patients about to start new lines of chemotherapy could be divided into groups with favourable and unfavourable prognosis on the basis of the number of CTCs measured with the analytically valid CellSearch system(Veridex, Raritan, NJ, USA) [3,[5][6][7][8][9][10][11][12][13]20]. When studying the association between the number of CTCs and evolution of the disease, researchers generally use a single cutpoint to identify favorable and unfavorable response groups, such as 5 CTCs for MBC [3,4,14], three for metastatic colorectal cancer [11], and five for castration resistant prostate cancer [7].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Assessment of CTC using CellSearch has been cleared by the Food and Drug Administration as a prognostic indicator, in conjunction with other clinical methods, for patients with metastatic breast, prostate, and colorectal cancers. Studies in metastatic breast, colorectal, and prostate cancer showed that patients about to start new lines of chemotherapy could be divided into groups with favourable and unfavourable prognosis on the basis of the number of CTCs measured with the analytically valid CellSearch system(Veridex, Raritan, NJ, USA) [3,[5][6][7][8][9][10][11][12][13]20]. When studying the association between the number of CTCs and evolution of the disease, researchers generally use a single cutpoint to identify favorable and unfavorable response groups, such as 5 CTCs for MBC [3,4,14], three for metastatic colorectal cancer [11], and five for castration resistant prostate cancer [7].…”
Section: Discussionmentioning
confidence: 99%
“…Circulating tumor cells (CTCs) have been shown to be an independent prognostic factor in metastatic breast cancer (MBC) [3][4][5][6], in metastatic prostate cancer [7][8][9][10] and in metastatic colorectal cancer [11,12]. They represent a promising tool for therapeutic monitoring: an elevated number of CTCs measured at any time in the clinical course were associated with a high likelihood of a very short time to progression.…”
Section: Introductionmentioning
confidence: 99%
“…Use of these identifying characteristics is supported by statistical observations that high counts of CTCs defined in this fashion correlate with poor prognosis . CTCs are most commonly extracted from circulation through an enrichment process by positive selection with EpCAM (also called CD326), a pan-epithelial marker (Nagrath, Sequist et al 2007;Shaffer, Leversha et al 2007;Olmos, Arkenau et al 2009;Stott, Hsu et al 2010;Stott, Lee et al 2010); this mechanism is employed by the CellSearch™ system and by other immunocapture systems (Danila, Heller et al 2007;de Bono, Scher et al 2008;Olmos, Arkenau et al 2009;Pantel and AlixPanabières 2010;Riethdorf and Pantel 2010;Pratt, Huang et al 2011). …”
Section: Introductionmentioning
confidence: 99%
“…It is now widely accepted that CTCs found in peripheral blood (PB) are involved in the process of hematogenous metastatic spread. CTCs migrate to distant sites for the establishment of secondary foci of disease, but should be mentioned that CTCs are ultimately rare (1)(2)(3)(4). Approximately one cancer cell per 100 million cells can be detected in the bloodstream (5).…”
mentioning
confidence: 99%
“…The presence of CTCs in PB is in general associated with a relatively shorter overall survival (1)(2)(3)(4)(5)(7)(8)(9). Capturing CTCs from blood has been assigned as a 'liquid biopsy'.…”
mentioning
confidence: 99%